Biocon Biologics sees traction in US biosimilars sales, no immediate plans for IPO

Biocon Biologics sees traction in US biosimilars sales, no immediate plans for IPO The company anticipates continued pricing pressure in the US but it is taking steps to mitigate this through increased volumes and market share, Deputy CEO Shreehas Tambe has said.

No comments:

Post a Comment